Novartis India Limited (NOVARTIND) Fair Value & Analysis
Healthcare · IN · Market cap ₹36.3B
Fair value as of: Jul 5, 2026
From 24 valuation models · updated today
Share price +10.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹759.30 – ₹1,555 · fair‑value band ₹313.87 – ₹679.85 · the ₹1,469 price screens above the ₹408.44 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Novartis India Limited (NOVARTIND) currently trades at ₹1,469, while our model-based Fair Value estimate is ₹408.44 — implying the stock looks roughly 72.2% overvalued today. We read business quality at 76/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Novartis India Limited generated revenue of ₹3.5B at a net margin of 26.3%. Revenue grew 8.0% year over year. It earns a return on equity of 11.6%. The stock trades on a trailing P/E of 38.9. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹313.87 (bear case) to ₹679.85 (bull case); at ₹1,469, the current price sits above that range. The share trades about 8% below its 52-week high and 96% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside — at -72%, NOVARTIND screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Novartis India Limited operates as a healthcare company in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neurosciences products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is based in Mumbai, India. The company is a subsidiary of Novartis AG.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Novartis India Limited reported revenue of ₹3.5B in FY2026 versus ₹3.9B in FY2022, a compound −2.2%/yr. Reported net income was ₹932M in FY2026.
Is NOVARTIND fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Novartis India Limited (NOVARTIND) undervalued?
What is the fair value of NOVARTIND?
What is the quality score of NOVARTIND?
What is the revenue of Novartis India Limited (NOVARTIND)?
What is the net profit margin of NOVARTIND?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.